Compare SANA & KBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SANA | KBDC |
|---|---|---|
| Founded | 2018 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 688.5M | 822.8M |
| IPO Year | 2021 | 2018 |
| Metric | SANA | KBDC |
|---|---|---|
| Price | $2.01 | $12.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | $8.43 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 2.6M | 417.6K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 12.43% |
| EPS Growth | ★ 17.24 | N/A |
| EPS | N/A | ★ 1.30 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.88 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.00 | $12.14 |
| 52 Week High | $5.49 | $15.87 |
| Indicator | SANA | KBDC |
|---|---|---|
| Relative Strength Index (RSI) | 32.21 | 50.55 |
| Support Level | N/A | $12.25 |
| Resistance Level | $3.41 | $13.55 |
| Average True Range (ATR) | 0.19 | 0.32 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 15.96 | 50.93 |
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company, investing mainly in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation mainly through debt investments in middle-market companies.